Form 6-K NOVO NORDISK A S For: Sep 20
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall Street ends higher on revived AI momentum
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- S&P Global explores potential separation of Capital IQ business
- JetBlue shares drop on creditor restructuring news amid bankruptcy filing fears
- Celestica (CLS) Tops Q3 EPS by 31c, Offers Guidance
- Equities end higher as Anthropic's IPO filing buoys AI stocks
TD Cowen Reiterates Buy Rating on Novo Nordisk (NVO) Following Monlunabant Obesity Update
September 20, 2024 10:12 AM EDTTD Cowen analyst Michael Nedelcovych reiterated a Buy rating and $155.00 price target on Novo Nordisk (NYSE: NVO) following the monlunabant obesity update.
The analyst commented, "In a Phase II obesity trial, CB1 blocker monlunabant showed weight loss in the ~6-7% range at 16 weeks. No serious... More



